Current characteristics associated with hereditary angioedema attacks and treatment: The home infusion based patient experience

被引:11
|
作者
Tachdjian, Raffi [1 ]
Banerji, Aleena [2 ]
Guyer, Autumn [2 ]
Morphew, Tricia [3 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Morphew Consulting LLC, Los Angeles, CA USA
关键词
C1 INHIBITOR DEFICIENCY; QUALITY-OF-LIFE; ECALLANTIDE TREATMENT; THERAPY; UPDATE; MANAGEMENT; BURDEN; RECOMMENDATIONS; EPIDEMIOLOGY; DEPRESSION;
D O I
10.2500/aap.2015.36.3832
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article presents a current perspective on the characteristics of hereditary angioedema (HAE) attacks and treatment as captured by a home infusion service. Retrospective data on 158 HAP patients who were enrolled in this acute treatment program were analyzed for factors surrounding an attack. The majority of patients had a high level of disease severity at baseline (88%), with a higher than expected likelihood of having a positive family history (87.8%). The most likely times for patients to call for home treatment were just before and during working hours (6:00 A.M.-5:00 P.M.). Eighty-three percent had more than one alternate mode of medication. Factors associated with a severe attack included an overall severe rating of HAP attacks in the previous year, an abdominal attack alone or a combination of peripheral and abdominal attacks versus a peripheral attack alone, and the use of two doses rather than one for treatment of the current attack. Average time to relief onset was 43.5 minutes. One dose of ecallantide was sufficient to treat the majority of attacks, and a second dose was needed in 23.6% of patients experiencing a severe attack. However, patients who reported both a severe attack rating during the previous year and experiencing only a peripheral current attack were more likely to experience a severe current attack. Acute treatment paradigms for HAP remain diverse. Understanding factors driving these decisions could help alleviate the overall burden of this disease and help overcome some of the challenges faced by the patients and their caretakers and improve their quality of life. Enhanced capture and analysis of prodromal factors in future studies should help us further alleviate the burden of this disease.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 50 条
  • [41] Universal Access to On-Demand Treatment of Patients with Hereditary Angioedema, the Chilean Experience
    Escobar, Juan J.
    Aguirre, Joaquin
    Ibanez, Samuel
    Cid, Barbara J.
    Campillay, Rolando
    Gallardo, Ana Maria
    Grau, Masumi
    Hoyos-Bachiloglu, Rodrigo
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2023, 36 (04) : 130 - 132
  • [42] Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2
    Fijen, Laure M.
    Bork, Konrad
    Cohn, Danny M.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2021, 61 (01) : 66 - 76
  • [43] Cost-utility analysis of Ruconest® (conestat alfa) compared to Berinert® P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema
    Kawalec, Pawel
    Holko, Przemyslaw
    Paszulewicz, Anna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2013, 30 (03): : 152 - 158
  • [44] rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency
    Lilian Varga
    Henriette Farkas
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (02) : 143 - 153
  • [45] Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate
    Martinez-Saguer, Inmaculada
    Rusicke, Eva
    Aygoren-Pursun, Emel
    Heller, Christine
    Klingebiel, Thomas
    Kreuz, Wolfhart
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2010, 203 (02) : 131.e1 - 131.e7
  • [46] Current treatment options for hereditary angioedema due to C1 inhibitor deficiency
    Wu, Maddalena Alessandra
    Zanichelli, Andrea
    Mansi, Marta
    Cicardi, Marco
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (01) : 27 - 40
  • [47] Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management
    West, Joseph B.
    Poarch, Kimberly
    Lumry, William R.
    CLINICAL THERAPEUTICS, 2021, 43 (12) : 2154 - +
  • [48] Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
    Soteres, Daniel F.
    Grimes, Fellicia
    CLINICAL CASE REPORTS, 2021, 9 (11):
  • [49] EFFICACY OF DIFFERENT MEDICAL THERAPIES FOR THE TREATMENT OF ACUTE LARYNGEAL ATTACKS OF HEREDITARY ANGIOEDEMA DUE TO C1-ESTERASE INHIBITOR DEFICIENCY
    Bork, Konrad
    Bernstein, Jonathan A.
    Machnig, Thomas
    Craig, Timothy J.
    JOURNAL OF EMERGENCY MEDICINE, 2016, 50 (04) : 567 - +
  • [50] Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
    Mendivil, Joan
    Murphy, Ryan
    de la Cruz, Marie
    Janssen, Ellen
    Boysen, Henrik Balle
    Jain, Gagan
    Aygoeren-Puersuen, Emel
    Hirji, Ishan
    Devercelli, Giovanna
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)